Dr. Mark A. Socinski is the Executive Medical Director of the Florida Hospital Cancer Institute. Dr. Socinski is a board-certified, fellowship-trained medical oncologist, specializing in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. He is an internationally recognized expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small-cell lung cancer. His research has focused on incorporating personalized medicine and molecular biomarkers in the treatment of lung cancer.
Dr. Socinski received his medical degree from the University of Vermont in Burlington, VT. He completed his medical residency in internal medicine at Beth Israel Hospital/Harvard Medical School and completed training in medical oncology at the Dana-Farber Cancer Institute/Harvard Medical School. Dr. Socinski holds memberships in numerous professional societies such as the American College of Physicians, American Society of Clinical Oncology, International Association for the Study of Lung Cancer, and the American College of Chest Physicians. He serves as co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute. He also serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance) and has been instrumental in the development of many cooperative clinical trials.